Use of the HPV MLPA assay in cervical cytology for the prediction of high grade lesions

Journal of Medical Virology

Volumn 85, Issue 8, 2013, Pages 1386-1393

  Litjens, Rogier J N T M ^a   Theelen, Wendy ^a   van de Pas, Yvonne ^a   Ossel, Jessica ^b   Reijans, Martin ^b   Simons, Guus ^b   Speel, Ernst Jan M ^a   Slangen, Brigitte F M ^a   Ramaekers, Frans C S ^a   Kruitwagen, Roy F P M ^a   Hopman, Anton H N ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b PathoFinder BV   (Netherlands)

Author keywords

Cervical cancer; Cytology; HPV; PCR; Viral integration

Indexed keywords

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER GRADING; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTODIAGNOSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DYSPLASIA; FEMALE; FOLLOW UP; GENOTYPE; HISTOPATHOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; MAJOR CLINICAL STUDY; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; POLYMERASE CHAIN REACTION; PREDICTION; PREDICTIVE VALUE; QUANTITATIVE ASSAY; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; VIRUS DNA CELL DNA INTERACTION; VIRUS LOAD; VIRUS TYPING; WART VIRUS;

ADULT; CYTOLOGICAL TECHNIQUES; FEMALE; HUMANS; MASS SCREENING; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PATHOLOGY, MOLECULAR; SENSITIVITY AND SPECIFICITY; UTERINE CERVICAL NEOPLASMS; VIRAL LOAD; VIRUS INTEGRATION; YOUNG ADULT;

HUMAN PAPILLOMAVIRUS;

EID: 84879182552     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.23629     Document Type: Article

References (35)

1. Begum S, Cao D, Gillison M, Zahurak M, Westra WH. 2005. Tissue distribution of human papillomavirus 16 DNA integration in patients with tonsillar carcinoma. Clin Cancer Res 11:5694-5699.
2. Bulkmans NW, Berkhof J, Rozendaal L, van Kemenade FJ, Boeke AJ, Bulk S, Voorhorst FJ, Verheijen RH, van Groningen K, Boon ME, Ruitinga W, van Ballegooijen M, Snijders PJ, Meijer CJ. 2007. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-Year follow-up of a randomised controlled implementation trial. Lancet 370:1764-1772.
3. Cannistra SA, Niloff JM. 1996. Cancer of the uterine cervix. N Engl J Med 334:1030-1038.
4. Carcopino X, Henry M, Mancini J, Giusiano S, Boubli L, Olive D, Tamalet C. 2012. Significance of HPV 16 and 18 viral load quantitation in women referred for colposcopy. J Med Virol 84:306-313.
5. Coutlee F, Ratnam S, Ramanakumar AV, Insinga RR, Bentley J, Escott N, Ghatage P, Koushik A, Ferenczy A, Franco EL. 2011. Distribution of human papillomavirus genotypes in cervical intraepithelial neoplasia and invasive cervical cancer in Canada. J Med Virol 83:1034-1041.
6. Cricca M, Morselli-Labate AM, Venturoli S, Ambretti S, Gentilomi GA, Gallinella G, Costa S, Musiani M, Zerbini M. 2007. Viral DNA load, physical status and E2/E6 ratio as markers to grade HPV16 positive women for high-grade cervical lesions. Gynecol Oncol 106:549-557.
7. Cuzick J, Mayrand MH, Ronco G, Snijders P, Wardle J. 2006. New dimensions in cervical cancer screening. Vaccine 24:S390-S397.
8. Cuzick J, Szarewski A, Cubie H, Hulman G, Kitchener H, Luesley D, McGoogan E, Menon U, Terry G, Edwards R, Brooks C, Desai M, Gie C, Ho L, Jacobs I, Pickles C, Sasieni P. 2003. Management of women who test positive for high-risk types of human papillomavirus: The HART study. Lancet 362:1871-1876.
9. Dalstein V, Riethmuller D, Pretet JL, Le Bail Carval K, Sautiere JL, Carbillet JP, Kantelip B, Schaal JP, Mougin C. 2003. Persistence and load of high-risk HPV are predictors for development of high-grade cervical lesions: A longitudinal French cohort study. Int J Cancer 106:396-403.
10. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. 2010. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893-2917.
11. Hellberg D, Nilsson S, Valentin J. 1994. Positive cervical smear with subsequent normal colposcopy and histology-frequency of CIN in a long-term follow-up. Gynecol Oncol 53:148-151.
12. Hopman AH, Smedts F, Dignef W, Ummelen M, Sonke G, Mravunac M, Vooijs GP, Speel EJ, Ramaekers FC. 2004. Transition of high-grade cervical intraepithelial neoplasia to micro-invasive carcinoma is characterized by integration of HPV 16/18 and numerical chromosome abnormalities. J Pathol 202:23-33.
13. Hudelist G, Manavi M, Pischinger KI, Watkins-Riedel T, Singer CF, Kubista E, Czerwenka KF. 2004. Physical state and expression of HPV DNA in benign and dysplastic cervical tissue: different levels of viral integration are correlated with lesion grade. Gynecol Oncol 92:873-880.
14. Insinga RP, Glass AG, Rush BB. 2004. Diagnoses and outcomes in cervical cancer screening: A population-based study. Am J Obstet Gynecol 191:105-113.
15. Jacobs MV, Snijders PJ, van den Brule AJ, Helmerhorst TJ, Meijer CJ, Walboomers JM. 1997. A general primer GP5+/GP6(+)-mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings. J Clin Microbiol 35:791-795.
16. Klaes R, Woerner SM, Ridder R, Wentzensen N, Duerst M, Schneider A, Lotz B, Melsheimer P, von Knebel Doeberitz M. 1999. Detection of high-risk cervical intraepithelial neoplasia and cervical cancer by amplification of transcripts derived from integrated papillomavirus oncogenes. Cancer Res 59:6132-6136.
17. Levi AW, Harigopal M, Hui P, Schofield K, Chhieng DC. 2011. Use of high-risk human papillomavirus testing in patients with low-grade squamous intraepithelial lesions. Cancer Cytopathol 119:228-234.
18. Lindh M, Gorander S, Andersson E, Horal P, Mattsby-Balzer I, Ryd W. 2007. Real-time Taqman PCR targeting 14 human papilloma virus types. J Clin Virol 40:321-324.
19. Mayrand MH, Duarte-Franco E, Rodrigues I, Walter SD, Hanley J, Ferenczy A, Ratnam S, Coutlee F, Franco EL. 2007. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med 357:1579-1588.
20. McQueen F, Duvall E. 2006. Using a quality control approach to define an 'adequately cellular' liquid-based cervical cytology specimen. Cytopathology 17:168-174.
21. Melnikow J, Nuovo J, Willan AR, Chan BK, Howell LP. 1998. Natural history of cervical squamous intraepithelial lesions: A meta-analysis. Obstet Gynecol 92:727-735.
22. Moberg M, Gustavsson I, Gyllensten U. 2004. Type-specific associations of human papillomavirus load with risk of developing cervical carcinoma in situ. Int J Cancer 112:854-859.
23. Monnier-Benoit S, Dalstein V, Riethmuller D, Lalaoui N, Mougin C, Pretet JL. 2006. Dynamics of HPV16 DNA load reflect the natural history of cervical HPV-associated lesions. J Clin Virol 35:270-277.
24. Peitsaro P, Johansson B, Syrjanen S. 2002. Integrated human papillomavirus type 16 is frequently found in cervical cancer precursors as demonstrated by a novel quantitative real-time PCR technique. J Clin Microbiol 40:886-891.
25. Pretorius RG, Zhang WH, Belinson JL, Huang MN, Wu LY, Zhang X, Qiao YL. 2004. Colposcopically directed biopsy, random cervical biopsy, and endocervical curettage in the diagnosis of cervical intraepithelial neoplasia II or worse. Am J Obstet Gynecol 191:430-434.
26. Rijkaart DC, Berkhof J, Rozendaal L, van Kemenade FJ, Bulkmans NW, Heideman DA, Kenter GG, Cuzick J, Snijders PJ, Meijer CJ. 2012a. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: Final results of the POBASCAM randomised controlled trial. Lancet Oncol 13:78-88.
27. Rijkaart DC, Berkhof J, van Kemenade FJ, Coupe VM, Hesselink AT, Rozendaal L, Heideman DA, Verheijen RH, Bulk S, Verweij WM, Snijders PJ, Meijer CJ. 2012b. Evaluation of 14 triage strategies for HPV DNA-positive women in population-based cervical screening. Int J Cancer 130:602-610.
28. Ronco G, van Ballegooijen M, Becker N, Chil A, Fender M, Giubilato P, Kurtinaitis J, Lancucki L, Lynge E, Morais A, O'Reilly M, Sparen P, Suteu O, Rebolj M, Veerus P, Zakelj MP, Anttila A. 2009. Process performance of cervical screening programmes in Europe. Eur J Cancer 45:2659-2670.
29. Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, Prey M, Raab S, Sherman M, Wilbur D, Wright T, Jr., Young N. 2002. The 2001 Bethesda system: Terminology for reporting results of cervical cytology. JAMA 287:2114-2119.
30. Tarkkanen J, Auvinen E, Nieminen P, Malmi R, Vartiainen J, Timonen T, Laurila P, Raisanen I, Unnerus HA, Sakki A, Mattila P, Van Den Brule AV, Tapper AM. 2007. HPV DNA testing as an adjunct in the management of patients with low-grade cytological lesions in Finland. Acta Obstet Gynecol Scand 86:367-372.
31. Theelen W, Reijans M, Simons G, Ramaekers FC, Speel EJ, Hopman AH. 2010a. A new multiparameter assay to assess HPV 16/18, viral load and physical status together with gain of telomerase genes in HPV-related cancers. Int J Cancer 126:959-975.
32. Theelen W, Speel EJ, Herfs M, Reijans M, Simons G, Meulemans EV, Baldewijns MM, Ramaekers FC, Somja J, Delvenne P, Hopman AH. 2010b. Increase in viral load, viral integration, and gain of telomerase genes during uterine cervical carcinogenesis can be simultaneously assessed by the HPV 16/18 MLPA-assay. Am J Pathol 177:2022-2033.
33. van den Brule AJ, Pol R, Fransen-Daalmeijer N, Schouls LM, Meijer CJ, Snijders PJ. 2002. GP5+/6+ PCR followed by reverse line blot analysis enables rapid and high-throughput identification of human papillomavirus genotypes. J Clin Microbiol 40:779-787.
34. Vinokurova S, Wentzensen N, Kraus I, Klaes R, Driesch C, Melsheimer P, Kisseljov F, Durst M, Schneider A, von Knebel Doeberitz M. 2008. Type-dependent integration frequency of human papillomavirus genomes in cervical lesions. Cancer Res 68:307-313.
35. Wright TC, Jr., Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D. 2007. 2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ. J Low Genit Tract Dis 11:223-239.